# Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

> **NCT01755078** · PHASE4 · COMPLETED · sponsor: **Chugai Pharma Taiwan** · enrollment: 166 (actual)

## Conditions studied

- Hemodialysis
- Hyperphosphatemia
- Cardiovascular Events

## Interventions

- **DRUG:** Sevelamer HCl
- **DRUG:** Calcium-based phosphate binder

## Key facts

- **NCT ID:** NCT01755078
- **Lead sponsor:** Chugai Pharma Taiwan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755078, "Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01755078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*